Navigating Your Path to Weight Management: How Often Do You Need to Take Wegovy?

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy injection is taken once weekly. The FDA-approved prescribing information directs that it be administered once weekly, on the same day each week, at any time of day, with or without meals. That answer now carries an important qualifier, because Wegovy is no longer only an injection: a tablet formulation of semaglutide for weight management was approved on December 22, 2025, and it is taken once daily rather than once weekly. So the honest answer to "how often" depends entirely on which formulation was dispensed to you — and the frequency printed on your pharmacy label always governs, not a general article.

What the Prescribing Information Actually Specifies

For Wegovy injection, the labeled frequency is once weekly by subcutaneous injection. The label states it may be taken at any time of day and does not require a relationship to meals, which reflects how the molecule behaves in the body rather than how it interacts with food.

For Wegovy tablets, the label specifies once-daily oral administration on an empty stomach. Oral semaglutide has to contend with the digestive tract before it reaches circulation, which is why its administration conditions are stricter than the injection's and why its dosing interval is shorter. Neither frequency is adjustable at will: both are part of the approved dosing regimen, and both are what every efficacy and safety figure in the label was generated under.

Why Once a Week Is Pharmacologically Possible

Most peptide hormones are cleared from the body within minutes. Semaglutide is engineered not to be. According to the clinical pharmacology section of the label, semaglutide has an elimination half-life of approximately one week, and maximum concentration is reached one to three days after a dose. That long half-life is the entire reason a weekly injection can maintain steady drug exposure rather than producing a spike and a trough.

The same property has a consequence people often do not expect. The label notes that with an elimination half-life of about one week, semaglutide will be present in the circulation for roughly five to seven weeks after the last injectable dose. Stopping is therefore not an immediate off switch, and neither starting nor stopping produces same-day effects.

Frequency Is Fixed. Strength Is Not.

The part that genuinely varies between people is not how often the medication is taken but which strength is being taken at any given point. Wegovy injection is supplied in six single-dose prefilled pen strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg — with the 7.2 mg presentation, marketed as Wegovy HD, approved on March 19, 2026. The tablet is supplied in 1.5 mg, 4 mg, 9 mg, and 25 mg.

The label describes a stepwise escalation across those strengths over an initial period before a maintenance dosage is reached, and it ties the pace of that escalation to tolerability. Where any individual lands, and how long they remain at each step, is a clinical judgment made by the prescriber based on response and side effects. It is not something a reader can calculate from an article, and it is not something we will attempt to specify here.

Missed Doses Are a Label-and-Prescriber Question

This is the follow-up question almost everyone asks, and it deserves a straight answer about why we are not going to print the rule. The missed-dose provisions in these labels are not interchangeable. The injection and the tablet carry different provisions from one another, and tirzepatide products carry a different provision again. A rule copied from the wrong product is worse than no rule at all.

Every dispensed Wegovy package includes the manufacturer's Instructions for Use and the patient information leaflet, and those documents are matched to the exact formulation and strength you were given. That is the correct source; your prescriber or dispensing pharmacist is the right person to ask.

What Weekly Dosing Produced in the Trials

The frequency question matters because the evidence base was built on it. In STEP 1, a 68-week double-blind trial of 1,961 adults with obesity, or with overweight plus at least one weight-related coexisting condition and without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean change in body weight of −14.9% versus −2.4% with placebo, an estimated treatment difference of −12.4 percentage points.

Weight reductions of 5% or more were achieved by 86.4% of the semaglutide group versus 31.5% of placebo, 10% or more by 69.1% versus 12.0%, and 15% or more by 50.5% versus 4.9%. Those numbers describe what happened under a specific weekly regimen sustained for well over a year alongside lifestyle intervention. They are not a description of what any individual will experience.

Wegovy's Approved Uses Go Beyond Weight Alone

It is worth knowing what the schedule is in service of. Wegovy injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and in pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

Note the phrase "maintain weight reduction long term." The labeled purpose is not a short course. That framing is the reason the dosing interval is designed for indefinite continuation rather than for a finite cycle.

Compounded Semaglutide Follows a Prescription, Not the Wegovy Label

Compounded semaglutide is a different regulatory category. It is not an FDA-approved finished product, and the FDA states plainly that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before they are marketed. It is prepared by a licensed pharmacy against a prescription written for an individual patient.

Because it is not the approved product, its schedule comes from the prescription and the dispensing pharmacy's own labeling rather than from the Wegovy prescribing information. Wegovy and Ozempic are the FDA-approved semaglutide brands; a compounded preparation is not a generic version of either one, and it should never be described that way.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How often do you take Wegovy?

Wegovy injection is administered once weekly. The prescribing information directs that it be given once weekly, on the same day each week, at any time of day, with or without meals. Wegovy tablets are a separate formulation and are taken once daily on an empty stomach. Which schedule applies to you depends on which formulation your prescriber selected, and the frequency printed on your pharmacy label governs.

Why is Wegovy injection weekly instead of daily?

Because of how long semaglutide stays in the body. The label reports an elimination half-life of approximately one week, with maximum concentration reached one to three days after a dose. That extended half-life allows a single weekly injection to maintain relatively steady drug exposure. The oral tablet is dosed daily because absorption through the digestive tract works differently and requires more frequent administration.

Does the day of the week matter?

The label directs that Wegovy injection be taken on the same day each week. Consistency is what the regimen is built around, since steady weekly spacing is how drug exposure was maintained in the trials that supported approval. If a schedule change is being considered for practical reasons, that is a conversation for your prescriber or dispensing pharmacist, who can advise based on your specific product and current strength.

What should I do if I miss a dose?

Read the Instructions for Use and patient information that came with your specific product, and contact your prescriber or pharmacist if the situation is unclear. We deliberately do not print a missed-dose rule here, because the provisions differ between Wegovy injection, Wegovy tablets, and tirzepatide products. Applying the wrong product's rule is a real source of dosing error, so the dispensed label is the only reliable source.

Does taking Wegovy more often produce faster weight loss?

No, and the assumption is unsafe. The efficacy figures in the label were generated under the approved regimen, not under more frequent dosing, and the FDA has documented serious adverse events arising from semaglutide dosing errors. More frequent administration would increase exposure well beyond what was studied. Any change to how a medication is taken is a decision for the prescriber who wrote it, not a self-directed adjustment.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.